KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT07252739 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

130

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Neoplasm

Interventions

DRUG: MK-1084
BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Cetuximab
DRUG: Carboplatin
DRUG: Pemetrexed

Sponsor

Merck Sharp & Dohme LLC